Literature DB >> 23802942

Thioredoxin reductase was nitrated in the aging heart after myocardial ischemia/reperfusion.

Ke Wang1, Jie Zhang, Xiaoliang Wang, Xin Liu, Lin Zuo, Kehua Bai, Jianyu Shang, Lu Ma, Teng Liu, Li Wang, Wen Wang, Xinliang Ma, Huirong Liu.   

Abstract

The age-related loss of anti-oxidant defense reduces recovery from myocardial ischemia/reperfusion injury (MI/R) in aged people. Our previous data showed that inactivation of thioredoxin (Trx) was involved in enhanced aging MI/R injury. Thioredoxin reductase (TrxR), the enzyme known to regulate Trx, is less efficient with age. The aim of the current study was to determine why TrxR activity was reduced and whether reduced TrxR activity contributed to enhanced aging MI/R injury. Both Trx and TrxR activity were decreased in the aging heart, and this difference was further amplified after MI/R. However, MI/R injury did not change TrxR expression between young and aging rats. Increased nitrogen oxide (NOx) but decreased nitric oxide (NO) bioavailability (decreased phosphorylated vasodilator-stimulated phosphoprotein) was observed in aging hearts. Peroxynitrite (ONOO⁻) was increased in aging hearts and was further amplified after MI/R. TrxR nitration in young and aging hearts was detected by immunoprecipitation (anti-nitrotyrosine) followed by immunoblotting (anti-TrxR). Compared with young hearts, TrxR nitration was increased in the aging hearts, and this was further intensified after MI/R. The ONOO⁻ decomposition catalyst (FeTMPyp) reduced TrxR nitration and increased TrxR and Trx activity. More importantly, FeTMPyp attenuated the MI/R injury in aging hearts as evidenced by decreased caspase-3 and malondialdehyde (MDA) concentration and increased cardiac function. Increased ONOO⁻ nitrated TrxR in the aging heart as a post-translational modification, which may be related to the enhanced MI/R injury of aging rats. Interventions that inhibit nitration and restore TrxR activity might be a therapy for attenuating enhanced MI/R injury in aging heart.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23802942      PMCID: PMC3804317          DOI: 10.1089/rej.2013.1437

Source DB:  PubMed          Journal:  Rejuvenation Res        ISSN: 1549-1684            Impact factor:   4.663


  30 in total

Review 1.  Arterial and cardiac aging: major shareholders in cardiovascular disease enterprises: Part I: aging arteries: a "set up" for vascular disease.

Authors:  Edward G Lakatta; Daniel Levy
Journal:  Circulation       Date:  2003-01-07       Impact factor: 29.690

2.  Inhibition of iNOS protects the aging heart against beta-adrenergic receptor stimulation-induced cardiac dysfunction and myocardial ischemic injury.

Authors:  Dianyuan Li; Yan Qu; Ling Tao; Huirong Liu; Aihua Hu; Feng Gao; Said Sharifi-Azad; Zvi Grunwald; Xin-Liang Ma; Jian-Zhong Sun
Journal:  J Surg Res       Date:  2005-09-12       Impact factor: 2.192

3.  The thioredoxin system in aging muscle: key role of mitochondrial thioredoxin reductase in the protective effects of caloric restriction?

Authors:  Susanne Rohrbach; Stefanie Gruenler; Mirja Teschner; Juergen Holtz
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2006-05-04       Impact factor: 3.619

4.  Inhibition of thioredoxin reductase but not of glutathione reductase by the major classes of alkylating and platinum-containing anticancer compounds.

Authors:  Anne-Barbara Witte; Karin Anestål; Elin Jerremalm; Hans Ehrsson; Elias S J Arnér
Journal:  Free Radic Biol Med       Date:  2005-09-01       Impact factor: 7.376

5.  The mammalian cytosolic selenoenzyme thioredoxin reductase reduces ubiquinone. A novel mechanism for defense against oxidative stress.

Authors:  Ling Xia; Tomas Nordman; Jerker M Olsson; Anastassios Damdimopoulos; Linda Björkhem-Bergman; Ivan Nalvarte; Lennart C Eriksson; Elias S J Arnér; Giannis Spyrou; Mikael Björnstedt
Journal:  J Biol Chem       Date:  2002-11-14       Impact factor: 5.157

Review 6.  Thioredoxin-1 and posttranslational modifications.

Authors:  Judith Haendeler
Journal:  Antioxid Redox Signal       Date:  2006 Sep-Oct       Impact factor: 8.401

7.  Three-dimensional structure of a mammalian thioredoxin reductase: implications for mechanism and evolution of a selenocysteine-dependent enzyme.

Authors:  T Sandalova; L Zhong; Y Lindqvist; A Holmgren; G Schneider
Journal:  Proc Natl Acad Sci U S A       Date:  2001-07-31       Impact factor: 11.205

Review 8.  Nitric oxide, superoxide, and peroxynitrite in myocardial ischaemia-reperfusion injury and preconditioning.

Authors:  Péter Ferdinandy; Richard Schulz
Journal:  Br J Pharmacol       Date:  2003-02       Impact factor: 8.739

9.  Pro-thrombotic state induced by post-translational modification of fibrinogen by reactive nitrogen species.

Authors:  Caryn Vadseth; Jose M Souza; Leonor Thomson; Amy Seagraves; Chandrasekaran Nagaswami; Tomas Scheiner; Jim Torbet; Gaston Vilaire; Joel S Bennett; Juan-Carlos Murciano; Vladimir Muzykantov; Marc S Penn; Stanley L Hazen; John W Weisel; Harry Ischiropoulos
Journal:  J Biol Chem       Date:  2003-12-17       Impact factor: 5.157

10.  Expression of constitutive and inducible nitric oxide synthases in the vascular wall of young and aging rats.

Authors:  M R Cernadas; L Sánchez de Miguel; M García-Durán; F González-Fernández; I Millás; M Montón; J Rodrigo; L Rico; P Fernández; T de Frutos; J A Rodríguez-Feo; J Guerra; C Caramelo; S Casado
Journal:  Circ Res       Date:  1998-08-10       Impact factor: 17.367

View more
  2 in total

Review 1.  Age-associated pro-inflammatory remodeling and functional phenotype in the heart and large arteries.

Authors:  Mingyi Wang; Ajay M Shah
Journal:  J Mol Cell Cardiol       Date:  2015-02-07       Impact factor: 5.000

2.  Predicting the Cytotoxic Potency of Cigarette Smoke by Assessing the Thioredoxin Reductase Inhibitory Capacity of Cigarette Smoke Extract.

Authors:  Longjie Zhang; Min Ning; Yingbo Xu; Chenghui Wang; Guangshan Zhao; Qingqing Cao; Jinsong Zhang
Journal:  Int J Environ Res Public Health       Date:  2016-03-21       Impact factor: 3.390

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.